Dapagliflozin Effect on Hospital Admissions in Patients With CKD: A Post Hoc Analysis of the DAPA-CKD Trial

被引：0
|
作者：
Schechter, Meir [1 ,7 ]
Jongs, Niels [1 ]
Chertow, Glenn [2 ]
Mosenzon, Ofri [7 ,11 ]
McMurray, John [3 ]
Correa-Rotter, Ricardo [4 ]
Rossing, Peter [5 ]
Langkilde, Anna Maria [6 ]
Sjostrom, David [6 ]
Toto, Robert D. [8 ]
Wheeler, David C. [9 ]
Heerspink, Hiddo J. L. [1 ,10 ]
机构：
[1] Univ Med Ctr Groningen, Groningen, Netherlands
[2] Stanford Univ, Sch Med, Stanford, CA USA
[3] Univ Glasgow, Glasgow, Lanark, Scotland
[4] Natl Med Sci & Nutr Inst Salvador Zubiran, Mexico City, DF, Mexico
[5] Steno Diabet Ctr Copenhagen, Herlev, Denmark
[6] AstraZeneca, BioPharmaceut R&D, Gothenburg, Sweden
[7] Hadassah Univ, Med Ctr, Jerusalem, Israel
[8] UT Southwestern Med Ctr, Dept Internal Med, Dallas, TX USA
[9] UCL, Fac Med Sci, London, England
[10] George Inst Global Hlth, Newtown, NSW, Australia
[11] Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2022年 / 33卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
FR-OR26
引用
收藏
页码：25 / 25
页数：1
相关论文
共 50 条
  • [21] Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA-CKD Trial
    Chertow, Glenn M.
    Correa-Rotter, Ricardo
    Vart, Priya
    Jongs, Niels
    McMurray, John J. V.
    Rossing, Peter
    Langkilde, Anna Maria
    Sjostrom, C. David
    Toto, Robert D.
    Wheeler, David C.
    Heerspink, Hiddo J. L.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2023, 12 (09):
  • [22] Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial
    Wheeler, David C.
    Jongs, Niels
    Stefansson, Bergur, V
    Chertow, Glenn M.
    Greene, Tom
    Hou, Fan Fan
    Langkilde, Anna Maria
    McMurray, John J., V
    Rossing, Peter
    Nowicki, Michal
    Wittmann, Istvan
    Correa-Rotter, Ricardo
    Sjostrom, C. David
    Toto, Robert D.
    Heerspink, Hiddo J. L.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 (09) : 1647 - 1656
  • [23] DAPA-CKD: A Regional Analysis of Kidney and Cardiovascular Outcomes
    Correa-Rotter, Ricardo
    Vart, Priya
    Jongs, Niels
    Hou, Fan Fan
    Chertow, Glenn M.
    Langkilde, Anna Maria
    McMurray, John
    Rossing, Peter
    Sjostrom, David
    Stefansson, Bergur V.
    Toto, Robert D.
    Douthat, Walter
    Escudero, Elizabeth T.
    Isidto, Rey A.
    Khullar, Dinesh
    Bajaj, Harpreet S.
    Wheeler, David C.
    Heerspink, Hiddo J. L.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 724 - 724
  • [24] A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
    Wheeler, David C.
    Toto, Robert D.
    Stefansson, Bergur V.
    Jongs, Niels
    Chertow, Glenn M.
    Greene, Tom
    Hou, Fan Fan
    McMurray, John J. V.
    Pecoits-Filho, Roberto
    Correa-Rotter, Ricardo
    Rossing, Peter
    Sjostrom, C. David
    Umanath, Kausik
    Langkilde, Anna Maria
    Heerspink, Hiddo J. L.
    KIDNEY INTERNATIONAL, 2021, 100 (01) : 215 - 224
  • [25] THE EFFECT OF DAPAGLIFLOZIN IN PATIENTS WITH EGFR <30 ML/MIN/1.73M2: FINDINGS FROM THE DAPA-CKD TRIAL
    Chertow, G.
    Vart, P.
    Jongs, N.
    Toto, R.
    Gorriz, J. L.
    Hou, F. F.
    Mcmurray, J.
    Correa-Rotter, R.
    Rossing, P.
    Sjostrom, C. D.
    Stefansson, B. V.
    Langkilde, A. M.
    Wheeler, D. C.
    Heerspink, H. J. L.
    NEPHROLOGY, 2021, 26 : 33 - 34
  • [26] Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
    Jongs, Niels
    Greene, Tom
    Chertow, Glenn M.
    McMurray, John J., V
    Langkilde, Anna Maria
    Correa-Rotter, Ricardo
    Rossing, Peter
    Sjostrom, C. David
    Stefansson, Bergur, V
    Toto, Robert D.
    Wheeler, David C.
    Heerspink, Hiddo J. L.
    LANCET DIABETES & ENDOCRINOLOGY, 2021, 9 (11): : 755 - 766
  • [27] Generalizability of DAPA-CKD trial to the real-world setting of outpatient CKD clinics in Italy
    Minutolo, Roberto
    Liberti, Maria Elena
    Provenzano, Michele
    Garofalo, Carlo
    Borrelli, Silvio
    Iodice, Carmela
    De Nicola, Luca
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 (12) : 2591 - 2593
  • [28] Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial
    Heerspink, Hiddo J. L.
    Sjostrom, C. David
    Jongs, Niels
    Chertow, Glenn M.
    Kosiborod, Mikhail
    Hou, Fan Fan
    McMurray, John J., V
    Rossing, Peter
    Correa-Rotter, Ricardo
    Kurlyandskaya, Raisa
    Stefansson, Bergur, V
    Toto, Robert D.
    Langkilde, Anna Maria
    Wheeler, David C.
    EUROPEAN HEART JOURNAL, 2021, 42 (13) : 1216 - 1227
  • [29] Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis
    McEwan, Phil
    Boyce, Rebecca
    Sanchez, Juan Jose Garcia
    Sjostrom, C. David
    Stefansson, Bergur
    Nolan, Stephen
    Correa-Rotter, Ricardo
    Rossing, Peter
    Chertow, Glenn M.
    McMurray, John J., V
    Wheeler, David C.
    Heerspink, Hiddo J. L.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 (05) : 1260 - 1270
  • [30] The dapagliflozin and prevention of adverse outcomes in chronic kidney disease: results of the DAPA-CKD study
    Batyushin, Mikhail M.
    TERAPEVTICHESKII ARKHIV, 2021, 93 (06) : 713 - 723
12345